83.JPG)
The Longevity and Anti-Senescence Therapy Market Size is valued at USD 2,736.43 million in 2023 and is predicted to reach USD 4,121.54 million by the year 2030 at a 6.8 % CAGR during the forecast period for 2024-2030.
Longevity is an effective approach focuses on the extension of health span by slowing the rate of aging. This approach is considered as the most efficient way to combat various aging-related chronic illnesses and disabling conditions. Aging comprises a rising risk of developing a number of neurodegenerative disorders, cardiovascular disease, diabetes, osteoarthritis, and cancer, which are commonly referred to as age-related diseases (ARDs). In the recent years, the development of new interventions and rejuvenation strategies to increase health span by means of supplements and pharmaceuticals targeting aging-related pathologies are in spotlight of a new branch in geriatric medicine, geroscience. Longevity and Anti-Senescence Therapy is one of such therapy can be classified into four groups: pharmacological therapies, lifestyle related, molecular (genetic and epigenetic) and cellular.
The growing number of geriatric populations across the globe in recent years is expected to bolster demand for Longevity and Anti-Senescence Therapy Market. According to World Population Prospects 2019 (United Nations, 2019), Global population aged 65 or over was accounted for 703 Million. Globally, geriatric population is anticipated to double by 2050 to reach 1.5 billion. Increasing number of research and investment activities in the development of longevity and anti-senescence therapies is projected to positively influence the industry’s growth over the forecast period. Another key aspect including rising adoption of advanced technologies such as gene therapy, stem cell, and senolytics Drug Therapy is anticipated to trigger growth in near future. Escalating prevalence of target diseases, especially Cardiovascular Diseases, Neural Degenerative Diseases, Ophthalmology Disorders, Cancer, among the aging population is expected to assist in the growth of the market for Longevity and Anti-Senescence Therapy over the coming years.
The global Longevity and Anti-Senescence Therapy market is categorized on the basis of Therapy, Application and region. On the basis of Therapy, the market is segmented into Senolytic Drug Therapy, Gene Therapy, Cell Therapy, Mitochondrial Therapy, Immunotherapy, and Others. Based on Application the market is segmented into Longevity, Senescence Inhibition, Cardiovascular Diseases, Neural Degenerative Diseases, Ophthalmology Disorders, and Cancer. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among all, North America is expected to dominate the market during the analysis of forecast period.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2,736.43 Mn |
|
Revenue Forecast In 2031 |
USD 4,121.54 Mn |
|
Growth Rate CAGR |
CAGR of 6.0 % from 2024 to 2030 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2030 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2030 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Therapy, Applications |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Acorda Therapeutics, Agex Therapeutics, Antoxerene, Calico Life Sciences, Celgene, Cleara Biotech, Human Longevity Inc., Insilico Medicine, Oisin Biotechnology, Powervision Inc., Prana Biotechnology Ltd., Proteostasis Therapeutics Inc., Recursion Pharmaceuticals, Restorbio, Sierra Sciences Llc, Senex Biotechnology, Senolytic Therapeutics, Spotlight Bioscience, T.A. Sciences, Unity Biotechnology, Alkahest, Inc., Stealth BioTherapeutics, BIOPHYTIS BSA, SIWA Therapeutics, Rejuveron Life Sciences AG, Rubedo Life Sciences, Inc, Lineage Cell Therapeutics, Juvenescence Life, Longevity Biotech CohBar, Inc. (CWBR), Genome Protection Inc., Navitor Pharmaceuticals, Inc., Elevian, Inc., Other Prominent Players. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Longevity and Anti-Senescence Therapy Market Snapshot
Chapter 4. Global Longevity and Anti-Senescence Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Key Healthcare Companies
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Therapy Estimates & Trend Analysis
5.1. By Therapy & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Therapy:
5.2.1. Senolytic Drug Therapy
5.2.2. Gene Therapy
5.2.3. Cell Therapy
5.2.4. Mitochondrial Therapy
5.2.5. Immunotherapy
5.2.6. Others
Chapter 6. Market Segmentation 1: By Applications Estimates & Trend Analysis
6.1. By Applications & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Applications:
6.2.1. Longevity
6.2.2. Senescence Inhibition
6.2.3. Cardiovascular Diseases
6.2.4. Neural Degenerative Diseases
6.2.5. Ophthalmology Disorders
6.2.6. Cancer
Chapter 7. Longevity and Anti-Senescence Therapy Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) estimates and forecasts By Therapy, 2024-2031
7.1.2. North America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) estimates and forecasts By Applications, 2024-2031
7.1.3. North America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
7.2. Europe
7.2.1. Europe Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, 2024-2031
7.2.2. Europe Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, 2024-2031
7.2.3. Europe Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, 2024-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, 2024-2031
7.3.2. Asia Pacific Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, 2024-2031
7.3.3. Asia Pacific Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, 2024-2031
7.4. Latin America
7.4.1. Latin America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, (US$ Million), 2024-2031
7.4.2. Latin America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, (US$ Million) 2024-2031
7.4.3. Latin America Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, (US$ Million) 2024-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Therapy, (US$ Million) 2024-2031
7.5.2. Middle East & Africa Longevity and Anti-Senescence Therapy Market revenue (US$ Million) By Applications, (US$ Million) 2024-2031
7.5.3. Middle East & Africa Longevity and Anti-Senescence Therapy Market revenue (US$ Million) by country, (US$ Million) 2024-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Acorda Therapeutics
8.2.2. Agex Therapeutics
8.2.3. Antoxerene
8.2.4. Calico Life Sciences
8.2.5. Celgene
8.2.6. Cleara Biotech
8.2.7. Human Longevity Inc.
8.2.8. Insilico Medicine
8.2.9. Oisin Biotechnology
8.2.10. Powervision Inc.
8.2.11. Prana Biotechnology Ltd.
8.2.12. Proteostasis Therapeutics Inc.
8.2.13. Recursion Pharmaceuticals
8.2.14. Restorbio
8.2.15. Sierra Sciences Llc
8.2.16. Senex Biotechnology
8.2.17. Senolytic Therapeutics
8.2.18. Spotlight Bioscience
8.2.19. T.A. Sciences
8.2.20. Unity Biotechnology
8.2.21. Alkahest, Inc.
8.2.22. Stealth BioTherapeutics
8.2.23. BIOPHYTIS BSA
8.2.24. SIWA Therapeutics
8.2.25. Rejuveron Life Sciences AG
8.2.26. Rubedo Life Sciences, Inc
8.2.27. Lineage Cell Therapeutics
8.2.28. Juvenescence Life
8.2.29. Longevity Biotech CohBar, Inc. (CWBR)
8.2.30. Genome Protection Inc.
8.2.31. Navitor Pharmaceuticals, Inc.
8.2.32. Elevian, Inc.
8.2.33. Velabs Therapeutics
8.2.34. Other Prominent Player
Global Longevity and Anti-Senescence Therapy Market Based on Therapy
Global Longevity and Anti-Senescence Therapy Market Based on Application
Global Longevity and Anti-Senescence Therapy Market Based on Region
Europe
North America
Asia Pacific
Latin America
Middle East & Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
